CD70 CAR T-cells / Shanghai Yake Biotech - LARVOL DELTA

GLOFITAMAB DEMONSTRATES SUPERIOR EFFICACY COMPARED WITH SECOND-DIFFERENT-TARGET CAR-T AS SALVAGE THERAPY AFTER CD19 CAR-T FAILURE IN R/R B-CELL NON-HODGKIN LYMPHOMA (EHA 2026) - "Characteristic Second-different-target CAR-T Salvage therapyn=77 (A group BsAb (CD3-CD20) Salvage therapyn=19) (B group Age Median(min:mas) 51(20-82) 55(26-68) Age>60y 25(32.5%) 4(21.1%) Sex,male 39(50.6%) 15(78.9%) ECOG 0-1 51(66.2%) 16(84.2%) ≥2 26(33.8%) 3(15.8%) Ann Arbor stage Ⅰ - Ⅱ 5(6.5%) 2(10.5%) Ⅲ - Ⅳ 72(93.5%) 17(89.5%) IPI 0-1 16(20.8%) 5(26.3%) 2 14(18.2%) 2(10.5%) 3 28(36.4%) 8(42.1%) 4-5 19(24.7%) 4(21.1%) Histology DLBCL 57(74.0%) 13(68.4%) FL/tFL 4(5.2%) 3(15.8%) BL 5(6.5%) 1(5.3%) SCNSL 5(6.5%) 2(10.5%) MCL 3(3.9%) PMBL 2(2.6%) Richter 1(1.3%) Best response after CD19 CART CR 16(20.8%) 6(31.6%) PR 22(28.6%) 2(10.5%) SD 11(14.3%) PD 27(35.1%) 11(57.9%) Not evaluated 1(1.3%) Failure post-CD19 CART Early failure(<6 months) 61(79.2%) 9(47.4%) Late failure(≥6 months) 16(20.8%) 10(52.6%) The median time from CD19 CART treatment to PD 2.8mrange:0.46~21.27m 4.9mrange0.5~38.2m Other Targets CART CD20 CART 58(75.3%) CD22 CART 15(19.5%) CD79b CART 3(3.9%)..."

CAR T-Cell Therapy • Clinical • B Cell Non-Hodgkin Lymphoma • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Secondary Central Nervous System Lymphoma • CD22 • CD70 • CD79B

CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases (clinicaltrials.gov) - P1; N=108; Recruiting; Sponsor: Zhejiang University; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology